Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in peptides and proteins and identify biomarkers related to cancer.
PURPOSE: This research study is looking at blood samples from patients with malignant melanoma, metastatic breast cancer, advanced lung cancer, pancreatic cancer, or colorectal cancer.
|Study Design:||Observational Model: Other
Time Perspective: Prospective
|Official Title:||Collaborative Project on Potential Serum Markers for Malignant Melanoma, Metastatic Breast, Advanced Lung Pancreatic Carcinoma and Colorectal Cancer|
- Detection of peptide and protein markers in serum [ Time Frame: Ongoing ]
- Identification of the protein/peptide involved [ Time Frame: Ongoing ]
|Study Start Date:||August 2008|
|Study Completion Date:||January 2017|
|Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
- To assess which potential peptide and protein markers produced by human melanoma, lung, breast, pancreatic, and colorectal cell lines may be detectable in serum of patients from these five disease groups.
- To conduct further extensive investigation with respect to identification of the protein/peptide involved, determination of specificity for each cancer, and development of more sensitive assays to look for such markers in a wider population of patients, including those undergoing therapy.
OUTLINE: This is a multicenter study.
Blood samples are collected before surgical intervention or treatment to assess peptide and protein markers.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00974610
|Cork University Hospital|
|Mercy University Hospital|
|Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital|
|Dublin, Ireland, 24|
|St. Vincent's University Hospital|
|Dublin, Ireland, 4|
|Mater Misericordiae University Hospital|
|Dublin, Ireland, 7|
|St. James's Hospital|
|Dublin, Ireland, 8|
|Dublin, Ireland, 9|
|Mater Private Hospital|
|St Luke's Hospital|
|University College Hospital|
|Letterkenny General Hospital|
|Mid-Western Cancer Centre at Mid-Western Regional Hospital|
|Limerick, Ireland, 0009|
|Waterford Regional Hospital|
|Principal Investigator:||Martin Clynes||National Institute for Cellular Biotechnology at Dublin City University|